Medical Marijuana Is Going Mainstream, But Big Pharma Still Has a Complicated Relationship With Cannabis Medicine
Medical marijuana has moved far beyond the stereotypical image of a young recreational consumer. Today, people across generations are turning to cannabis and cannabinoid products for a growing list of reasons, including pain relief, sleep, relaxation, chemotherapy-related symptoms and other medical concerns. Â As a plant helping people, it hs many use and opportunities, leading to the complicated relationship between big pharmaceutical companies and cannabis.
The Fresh Toast – As the industry tries to find a balance, you have to look at the complicated relationship between big pharmaceutical companies and cannabis.
The shift is particularly notable among older Americans. According to AARP-supported research, 21% of adults age 50 and older reported using some form of cannabis in the previous year. Among those older users, 63% said they used cannabis for pain relief and 68% said they used it to help with sleep.
The broader public appears to be increasingly comfortable with the idea of cannabis as medicine. Pew Research Center found in 2024 88% of Americans believed marijuana should be legal in some form, with 32% supporting medical use only and 57% supporting both medical and recreational use. Its January 2026 survey found essentially the same overall level of support: 55% favored legal medical and recreational use, while another 33% favored medical use only.
RELATED: Target’s Big Bet On Hemp
Yet there is a fascinating contradiction developing between consumer demand for medical cannabis and the traditional pharmaceutical industry.
The pharmaceutical industry’s relationship with cannabis is hardly straightforward. On one hand, pharmaceutical researchers have spent decades studying cannabinoids and attempting to isolate, standardize and reproduce their therapeutic properties. On the other, the broader cannabis industry has built a multibillion-dollar consumer market around products not necessarily fitting the conventional pharmaceutical model.
The distinction matters.
Traditional pharmaceutical companies make money by developing patentable drugs, securing regulatory approval and selling standardized products through the medical system. Cannabis, by comparison, is a plant with dozens of biologically active compounds, including THC and CBD. Consumers can purchase cannabis flower, edibles, tinctures, beverages and other products without going through the traditional prescription-drug pipeline.
The FDA has made the distinction clear. The agency says it has not approved cannabis itself to treat any disease or medical condition. However, it has approved one cannabis-derived prescription drug, Epidiolex, as well as three synthetic cannabis-related drugs: Marinol, Syndros and Cesamet.
This creates an unusual pharmaceutical paradox: Big Pharma can embrace individual cannabinoids as pharmaceutical ingredients while remaining far more cautious about cannabis as an entire plant.
There is also an economic issue.
A pharmaceutical company can spend hundreds of millions of dollars developing a molecule, conducting clinical trials and pursuing FDA approval when it believes the resulting product can be protected by intellectual property and sold at a profitable price.
Whole-plant cannabis is a different proposition.
If consumers can purchase cannabis-derived products from thousands of dispensaries, why would a pharmaceutical company want to compete with an agricultural product which can be cultivated, processed and sold in numerous forms?
The answer may increasingly be standardization.
RELATED: Another Study Shows Cannabis Is a Big Help for Boomers
Pharmaceutical companies can potentially take compounds found in cannabis and turn them into precisely dosed, clinically tested medicines designed for specific conditions. The approach gives physicians predictable dosing and gives manufacturers a regulatory pathway — but it can also produce products very different from the cannabis products consumers are already using.
Cannabis also occupies a complicated place in the broader conversation about modern healthcare.
For cancer patients, cannabinoids have already found a place in medicine. FDA-approved dronabinol products, for example, have therapeutic uses including nausea associated with cancer chemotherapy.
Meanwhile, consumers continue experimenting with cannabis for pain, sleep and other health-related purposes. This does not mean every claim surrounding medical marijuana has been scientifically established. In fact, one of the biggest challenges facing cannabis medicine is the need for more rigorous clinical research.
But consumer behavior is increasingly forcing the medical establishment to pay attention.
The question is no longer simply whether people are interested in cannabis. Millions clearly are. The bigger question is what happens when a plant-based product becomes part of mainstream healthcare while federal regulation, pharmaceutical economics and clinical research are still catching up.
RELATED: Can This Green Plant Be Part Of Your Fountain Of Youth
The irony may be Big Pharma and cannabis are not necessarily destined to be competitors. They could become partners.
As cannabis research expands, pharmaceutical companies may increasingly look to cannabinoids as starting points for new medications. Cannabis companies, meanwhile, may seek pharmaceutical partnerships to help develop standardized formulations, conduct clinical trials and navigate the FDA approval process.
The result could be a two-track cannabis market: one side built around consumer medical marijuana and wellness products, and another built around highly regulated cannabinoid-based prescription medicines.
For consumers, it could ultimately mean more choices.
For Big Pharma, cannabis represents something considerably more complicated: a potential source of new medicines, a disruptive competitor and an enormous consumer market — all at the same time.
And as medical marijuana continues moving into the mainstream, the pharmaceutical industry may have little choice but to figure out exactly where it wants to sit in the cannabis economy.
